Empagliflozin restores autophagy and attenuates ponatinib-induced cardiomyocyte senescence and death

Vascul Pharmacol. 2024 Jun:155:107300. doi: 10.1016/j.vph.2024.107300.

Authors

Filippo Biondi¹, Sandra Ghelardoni², Stefania Moscato³, Letizia Mattii³, Serena Barachini³, Giuseppina Novo⁴, Riccardo Zucchi², Raffaele De Caterina¹, Rosalinda Madonna⁵

Affiliations

¹ Department of Pathology, Cardiology Division, University of Pisa, 56122 Pisa, Italy.
² Department of Pathology, Laboratory of Biochemistry, University of Pisa, 56122 Pisa, Italy.
³ Department of Clinical and Experimental Medicine, University of Pisa, 56122 Pisa, Italy.
⁴ Division of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Palermo, University of Palermo, 90121 Palermo, Italy.
⁵ Department of Pathology, Cardiology Division, University of Pisa, 56122 Pisa, Italy. Electronic address: rosalinda.madonna@unipi.it.

PMID: 38985602
DOI: 10.1016/j.vph.2024.107300

No abstract available

MeSH terms

Animals
Autophagy* / drug effects
Benzhydryl Compounds* / pharmacology
Cells, Cultured
Cellular Senescence* / drug effects
Glucosides* / pharmacology
Imidazoles* / pharmacology
Myocytes, Cardiac* / drug effects
Myocytes, Cardiac* / metabolism
Myocytes, Cardiac* / pathology
Protein Kinase Inhibitors / pharmacology
Pyridazines* / pharmacology
Rats
Signal Transduction / drug effects
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

Benzhydryl Compounds
ponatinib
empagliflozin
Imidazoles
Pyridazines
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
Protein Kinase Inhibitors